Research Use Recombinant Protein Market

研究執行與發布：MarketsandMarkets　·　發布日期 2026-08-04　·　464 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

完整報告名稱與涵蓋範圍

Research Use Recombinant Protein Market by Product (Cytokines, Growth Factors), Product Formulation (Lyophilized, Liquid), Species (Human, Mouse), Host Cell (Mammalian, Yeast), Application (Cell Culture), End User, Region - Global Forecast to 2031

報告摘要

The research use recombinant protein market is expected to reach USD 1.55 billion in 2031 from USD 1.11 billion in 2026, registering a CAGR of 7.0% during the forecast period. The market is primarily driven by the growing pipeline of recombinant therapeutics, rising preclinical research in advanced therapies, and increasing use of proteins in tumor microenvironment studies. Cytokines, chemokines, growth factors, antigens, receptors, ligands, and enzymes are widely used across drug discovery, immunology, oncology, stem cell research, disease modeling, and cell-based assay development. The shift toward human-expressed recombinant proteins is further improving biological relevance in complex research models. In addition, ready-to-use liquid formulations and bioengineered heat-stable protein variants present opportunities for automated, high-throughput, and continuous cell culture workflows. However, market growth is constrained by lot-to-lot variability, inconsistencies in off-the-shelf proteins, and the high cost of mammalian-expressed products. Emerging non-protein alternatives and increasing supply chain complexity also remain key challenges for manufacturers and research laboratories. “Human species segment to register highest CAGR during forecast period” By species, the human segment is projected to exhibit the highest CAGR in the research use recombinant protein market due to the increasing use of human-derived proteins in drug discovery, translational research, disease modeling, and advanced cell-based assays. Human cytokines, growth factors, chemokines, receptors, ligands, antigens, and enzymes are widely used across oncology, immunology, neuroscience, infectious disease, and stem cell research. Growing adoption of human cell lines, organoids, and physiologically relevant experimental models is increasing demand for high-purity, biologically active, and application-specific human recombinant proteins. “Cytokines & chemokines segment to hold largest market share in 2026” By product, the cytokines & chemokines segment is estimated to account for the largest share of the research use recombinant protein market, driven by their extensive use in immunology, oncology, inflammation research, stem cell studies, and drug discovery. These proteins are essential for regulating immune-cell activation, proliferation, differentiation, and migration across cell-based assays and disease models. Growing demand for interleukins, interferons, colony-stimulating factors, and chemotactic proteins in organoid development, tumor microenvironment studies, biomarker research, and translational applications continues to strengthen the position of this segment. “US to register highest CAGR during forecast period” In the US, the research use recombinant protein market is expected to register the highest CAGR, driven by the strong presence of leading life science companies, an advanced biomedical research infrastructure, and a high adoption rate of recombinant proteins in drug discovery and preclinical research. Expanding pipelines of recombinant therapeutics, rising research in cell and gene therapies, immuno-oncology, stem cell biology, and tumor microenvironment studies are key factors driving market growth. Human-expressed cytokines, growth factors, chemokines, antigens, receptors, and enzymes are increasingly used across pharmaceutical companies, biotechnology firms, CROs, and academic research institutes, further supporting demand. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side – 70% and Demand Side– 30% • By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25% • By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, Middle East & Africa – 5% Thermo Fisher Scientific Inc. (US), Bio-Techne (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity (US), BPS Bioscience, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sartorius AG (Germany), Sino Biological, Inc. (China), GenScript (China), Proteintech Group, Inc. (US), Miltenyi Biotec (Germany), Enzo Biochem Inc. (US), Abnova Corporation (Taiwan), STEMCELL Technologies (Canada), RayBiotech, Inc. (US), ProSpec-Tany TechnoGene Ltd. (Israel), ProteoGenix (France), Aviva Systems Biology Corporation (US), Elabscience (US), Qkine Ltd. (UK), Abbexa (UK), Bon Opus Biosciences, LLC (US), Novoprotein Scientific Inc. (China), and OriGene Technologies, Inc. (US) are some of the key companies offering research use recombinant proteins. Research Coverage This research report categorizes the research use recombinant protein market by product (cytokines & chemokines, growth factors, recombinant antigens, receptors & ligands, enzymes, ECM & adhesion proteins, and other recombinant proteins), product formulation (lyophilized and liquid recombinant proteins), species (human, mouse, rat, non-human primate, and other species), host cell (mammalian cells, insect cells, bacterial cells, yeast & fungi cells, and other host cells), application (cell culture & differentiation, drug discovery, cancer research, stem cell research, infectious disease & vaccine research, and other applications), end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the research use recombinant protein market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the research use recombinant protein market. This report also includes a competitive analysis of emerging startups in the research use recombinant protein industry ecosystem. Key Benefits of Buying the Report The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (growing pipeline for recombinant therapeutic proteins, rising preclinical research activities in advanced therapies, shift towards human-expressed recombinant proteins for research use applications, increase in demand for research use recombinant proteins in tumor microenvironment studies), restraints (high lot-to-lot variability and inconsistency in off-the-shelf recombinant proteins for research use applications, high costs associated with premium recombinant proteins expressed in mammalian cells), opportunities (emergence of ready-to-use liquid formulations for integration into automated high-throughput workflows, development of bio-engineered, heat-stable protein variants for continuous cell lines & cell culture), and challenges (advent of non-protein mimics and alternative modalities, rising supply chain complexities) influencing the market growth • Product Development/Innovation: Detailed insights into newly launched products and innovations in the research use recombinant protein market • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the research use recombinant protein market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, such as Thermo Fisher Scientific Inc. (US), Bio-Techne (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity (US), BPS Bioscience, Inc. (US), Bio-Rad Laboratories, Inc. (US), and Sartorius AG (Germany), among others, for the research use recombinant protein market

授權報價

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

目錄 Table of Contents

1 INTRODUCTION 37 1.1 STUDY OBJECTIVES 37 1.2 MARKET DEFINITION 37 1.3 STUDY SCOPE 37 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 38 1.3.2 INCLUSIONS & EXCLUSIONS 39 1.3.3 YEARS CONSIDERED 39 1.3.4 CURRENCY CONSIDERED 40 1.4 STAKEHOLDERS 40 2 EXECUTIVE SUMMARY 41 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 41 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 43 2.3 DISRUPTIVE TRENDS IN RUO RECOMBINANT PROTEIN MARKET 44 2.4 HIGH-GROWTH SEGMENTS 45 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 46 3 PREMIUM INSIGHTS 47 3.1 RUO RECOMBINANT PROTEIN MARKET OVERVIEW 47 3.2 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION 48 3.3 RUO RECOMBINANT PROTEIN MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49 3.4 RUO RECOMBINANT PROTEIN MARKET SHARE, BY END USER, 2026 VS 2031 (%) 50 4 MARKET OVERVIEW 51 4.1 INTRODUCTION 51 4.2 MARKET DYNAMICS 52 4.2.1 DRIVERS 53 4.2.1.1 Growing pipeline for recombinant therapeutic proteins 53 4.2.1.2 Rising preclinical research in advanced therapies (cell & gene therapies) 54 4.2.1.3 Shift toward human-expressed recombinant proteins for RUO applications 55 4.2.1.4 Rising demand for RUO recombinant proteins in tumor microenvironment studies 55 4.2.2 RESTRAINTS 56 4.2.2.1 High lot-to-lot variability and inconsistency in off-the-shelf recombinant proteins for research-use applications 56 4.2.2.2 High costs associated with premium recombinant proteins expressed in mammalian cells 57 4.2.3 OPPORTUNITIES 57 4.2.3.1 Emergence of ready-to-use liquid formulations for integration into automated high-throughput workflows 57 4.2.3.2 Development of bioengineered, heat-stable protein variants for continuous cell lines & cell culture 58 4.2.4 CHALLENGES 58 4.2.4.1 Advent of non-protein mimics and alternative modalities 58 4.2.4.2 Rising supply chain complexities 59 4.3 UNMET NEEDS AND WHITE SPACES 59 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 61 5 INDUSTRY TRENDS 62 5.1 PORTER’S FIVE FORCES ANALYSIS 62 5.1.1 INTENSITY OF COMPETITIVE RIVALRY 63 5.1.2 BARGAINING POWER OF SUPPLIERS 63 5.1.3 BARGAINING POWER OF BUYERS 64 5.1.4 THREAT OF SUBSTITUTES 64 5.1.5 THREAT OF NEW ENTRANTS 64 5.2 MACROECONOMIC OUTLOOK 64 5.2.1 INTRODUCTION 64 5.2.2 GDP TRENDS AND FORECASTS 65 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 65 5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY 66 5.3 VALUE CHAIN ANALYSIS 66 5.4 ECOSYSTEM ANALYSIS 68 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 69 5.5 PRICING ANALYSIS 70 5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025 71 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 72 5.6 TRADE ANALYSIS 74 5.6.1 IMPORT SCENARIO (HS CODE 3822.00) 74 5.6.2 EXPORT SCENARIO (HS CODE 3822.00) 75 5.7 KEY CONFERENCES & EVENTS, 2026–2027 76 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77 5.9 INVESTMENT & FUNDING SCENARIO 77 5.10 CASE STUDY ANALYSIS 79 5.10.1 RECOMBINANT LIGAND SCREENING MAPS INFLAMED INTESTINAL ORGANOID RESPONSES 79 5.10.2 RECOMBINANT OSTEOGLYCIN SUPPORTS ALVEOLAR ORGANOID RESEARCH 79 5.10.3 RECOMBINANT ANTIGENS IMPROVE H. PYLORI ASSAY DEVELOPMENT 79 5.11 IMPACT OF US TARIFFS—RUO RECOMBINANT PROTEIN MARKET 79 5.11.1 INTRODUCTION 79 5.11.2 KEY TARIFF RATES 80 5.11.3 PRICE IMPACT ANALYSIS 81 5.11.4 IMPACT ON COUNTRIES/REGIONS 82 5.11.4.1 US 82 5.11.4.2 Europe 83 5.11.4.3 Asia Pacific 83 5.11.5 IMPACT ON END-USE INDUSTRIES 84 5.11.5.1 Pharmaceutical & biotechnology companies 84 5.11.5.2 Academic & research institutes 84 5.11.5.3 CROs 85 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86 6.1 INTRODUCTION 86 6.2 KEY TECHNOLOGIES 86 6.2.1 CODON OPTIMIZATION 86 6.2.2 CRISPR/CAS9 ENGINEERING 87 6.2.3 TRANSIENT GENE EXPRESSION (TGE) 87 6.3 COMPLEMENTARY TECHNOLOGIES 87 6.3.1 AFFINITY CHROMATOGRAPHY 87 6.3.2 TANGENTIAL FLOW FILTRATION (TFF) AND ULTRAFILTRATION 88 6.4 ADJACENT TECHNOLOGIES 88 6.4.1 GENE EDITING 88 6.4.2 SPATIAL MULTI-OMICS 89 6.5 TECHNOLOGY ROADMAP 89 6.6 PATENT ANALYSIS 90 6.6.1 METHODOLOGY 90 6.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 90 6.6.3 LIST OF KEY PATENTS 92 6.7 FUTURE APPLICATIONS 93 6.8 IMPACT OF AI/GEN AI ON RUO RECOMBINANT PROTEIN MARKET 93 6.8.1 TOP USE CASES AND MARKET POTENTIAL 94 6.8.2 BEST PRACTICES IN AI-ENABLED RECOMBINANT PROTEIN DISCOVERY, DESIGN, AND WORKFLOWS 95 6.8.3 CASE STUDIES OF AI IMPLEMENTATION IN RUO RECOMBINANT PROTEIN MARKET 95 6.8.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 96 6.8.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED RECOMBINANT PROTEIN SOLUTIONS 96 7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 98 7.1 REGIONAL REGULATIONS AND COMPLIANCE 98 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 7.1.2 INDUSTRY STANDARDS 102 7.1.2.1 North America 102 7.1.2.2 Europe 102 7.1.2.3 Asia Pacific 103 7.1.2.4 Rest of the world 104 7.2 SUSTAINABILITY INITIATIVES 104 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 105 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 105 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 109 8.1 DECISION-MAKING PROCESS 109 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 109 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 109 8.2.2 KEY BUYING CRITERIA, BY END USER 110 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 112 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 112 9 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY PRODUCT 114 9.1 INTRODUCTION 115 9.2 CYTOKINES & CHEMOKINES 115 9.2.1 EXPANDING IMMUNE-CELL RESEARCH TO BOOST MARKET GROWTH 115 9.3 GROWTH FACTORS 119 9.3.1 EXPANDING STEM CELL, ORGANOID, AND TISSUE-MODEL RESEARCH TO FUEL SEGMENT GROWTH 119 9.4 RECOMBINANT ANTIGENS 122 9.4.1 INFECTIOUS-DISEASE AND ANTIBODY RESEARCH TO DRIVE MARKET 122 9.5 RECEPTORS & LIGANDS 126 9.5.1 INCREASING USE OF RECOMBINANT RECEPTORS AND LIGANDS TO DRIVE MARKET 126 9.6 ENZYMES 129 9.6.1 EXPANDING MOLECULAR RESEARCH TO DRIVE MARKET 129 9.7 ECM & ADHESION PROTEINS 133 9.7.1 STEM CELL AND 3D CULTURE RESEARCH TO DRIVE MARKET 133 9.8 OTHER RECOMBINANT PROTEINS 136 10 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION 140 10.1 INTRODUCTION 141 10.2 LYOPHILIZED RECOMBINANT PROTEINS 141 10.2.1 IMPROVED STABILITY, SIMPLIFIED DISTRIBUTION, AND CONSISTENT RESEARCH PERFORMANCE TO DRIVE MARKET GROWTH 141 10.3 LIQUID RECOMBINANT PROTEINS 145 10.3.1 CONVENIENCE, PRECISE DOSING, AND AUTOMATION-COMPATIBLE WORKFLOWS TO SUPPORT GROWTH 145 11 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY SPECIES 149 11.1 INTRODUCTION 150 11.2 HUMAN 150 11.2.1 EXPANDING HUMAN-RELEVANT MODELS AND TRANSLATIONAL RESEARCH TO BOOST MARKET GROWTH 150 11.3 MOUSE 154 11.3.1 EXPANDING MURINE DISEASE MODELS AND SPECIES-MATCHED CELL CULTURE WORKFLOWS TO FUEL SEGMENT 154 11.4 RAT 157 11.4.1 EXPANDING RAT-BASED PRECLINICAL MODELS AND SPECIES-MATCHED RESEARCH WORKFLOWS TO DRIVE MARKET 157 11.5 NON-HUMAN PRIMATE 161 11.5.1 EXPANDING TRANSLATIONAL VALIDATION AND ADVANCED BIOLOGIC DEVELOPMENT TO DRIVE MARKET 161 11.6 OTHER SPECIES 164 12 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY HOST CELL 168 12.1 INTRODUCTION 169 12.2 MAMMALIAN CELLS 169 12.2.1 GROWING BIOLOGICS RESEARCH TO BOOST MARKET GROWTH 169 12.3 BACTERIAL CELLS 173 12.3.1 COST-EFFECTIVE AND RAPID PROTEIN PRODUCTION TO DRIVE MARKET 173 12.4 INSECT CELLS 176 12.4.1 GROWING RESEARCH ON COMPLEX PROTEINS AND VIRAL TARGETS TO FUEL GROWTH 176 12.5 YEAST & FUNGI CELLS 180 12.5.1 SCALABLE AND COST-EFFICIENT PROTEIN PRODUCTION TO DRIVE MARKET 180 12.6 OTHER HOST CELLS 183 13 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY APPLICATION 187 13.1 INTRODUCTION 188 13.2 CELL CULTURE & DIFFERENTIATION 188 13.2.1 GROWTH IN STEM-CELL, ORGANOID, AND ADVANCED CELL-CULTURE RESEARCH TO BOOST MARKET GROWTH 188 13.3 DRUG DISCOVERY 192 13.3.1 EXPANDING BIOLOGICS RESEARCH AND TARGET SCREENING TO FUEL SEGMENT 192 13.4 CANCER RESEARCH 195 13.4.1 EXPANDING IMMUNO-ONCOLOGY AND PRECISION CANCER RESEARCH TO DRIVE MARKET 195 13.5 STEM CELL RESEARCH 199 13.5.1 GROWTH IN STEM CELL, ORGANOID, AND REGENERATIVE MEDICINE RESEARCH TO DRIVE MARKET 199 13.6 INFECTIOUS DISEASE & VACCINE RESEARCH 202 13.6.1 EMERGING PATHOGENS AND EVOLVING VIRAL STRAINS TO DRIVE MARKET 202 13.7 OTHER APPLICATIONS 206 14 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY END USER 210 14.1 INTRODUCTION 211 14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 212 14.2.1 EXPANDING THERAPEUTIC PIPELINES, ADVANCED CELL MODELS, AND ENGINEERED PROTEINS TO BOOST MARKET GROWTH 212 14.3 ACADEMIC & RESEARCH INSTITUTES 215 14.3.1 PUBLIC RESEARCH FUNDING AND ADVANCED HUMAN DISEASE MODELS TO FUEL SEGMENT 215 14.4 CONTRACT RESEARCH ORGANIZATIONS 219 14.4.1 EXPANDING R&D OUTSOURCING TO DRIVE MARKET 219 14.5 OTHER END USERS 222 15 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY REGION 226 15.1 INTRODUCTION 227 15.2 NORTH AMERICA 228 15.2.1 US 232 15.2.1.1 Research funding, advanced cellular models, and engineered protein innovation to drive market 232 15.2.2 CANADA 236 15.2.2.1 Government funding and regenerative medicine leadership to propel market 236 15.3 EUROPE 239 15.3.1 GERMANY 243 15.3.1.1 Biotechnology clusters, translational research, and supplier expansion to aid market growth 243 15.3.2 UK 247 15.3.2.1 Advanced cellular models and animal-origin-free protein innovation to drive market 247 15.3.3 FRANCE 250 15.3.3.1 Immuno-oncology research to drive market 250 15.3.4 ITALY 254 15.3.4.1 Advanced research infrastructure and biotechnology collaboration to drive market 254 15.3.5 SPAIN 257 15.3.5.1 AI-enabled protein design and collaborative biomedical infrastructure to aid growth 257 15.3.6 REST OF EUROPE 261 15.4 ASIA PACIFIC 264 15.4.1 CHINA 269 15.4.1.1 AI-enabled protein engineering and localized reagent production to boost market 269 15.4.2 JAPAN 272 15.4.2.1 Regenerative medicine expertise and development of application-specific recombinant proteins to drive market growth 272 15.4.3 INDIA 276 15.4.3.1 Research outsourcing capabilities and expanding scientific infrastructure to propel market 276 15.4.4 AUSTRALIA 279 15.4.4.1 Integrated protein-research infrastructure and translational science to fuel market 279 15.4.5 SOUTH KOREA 283 15.4.5.1 Synthetic biology, organoid-based screening, and AI-enabled discovery to support market growth 283 15.4.6 REST OF ASIA PACIFIC 286 15.5 LATIN AMERICA 290 15.5.1 BRAZIL 294 15.5.1.1 Infectious-disease research, shared protein-production infrastructure, and vaccine innovation to drive market 294 15.5.2 MEXICO 297 15.5.2.1 Expanding use of high-quality recombinant proteins in global translational workflows to support market 297 15.5.3 REST OF LATIN AMERICA 301 15.6 MIDDLE EAST 304 15.6.1 GCC COUNTRIES 307 15.6.1.1 Saudi Arabia 311 15.6.1.1.1 Biotechnology policy and advanced-therapy infrastructure to boost market 311 15.6.1.2 UAE 315 15.6.1.2.1 AI-enabled human-relevant models and integrated biotechnology infrastructure to aid market growth 315 15.6.1.3 Rest of GCC Countries 318 15.6.2 REST OF MIDDLE EAST 322 15.7 AFRICA 325 15.7.1 INFECTIOUS-DISEASE RESEARCH AND LOCALIZED RECOMBINANT PROTEIN PRODUCTION TO PROPEL MARKET 325 16 COMPETITIVE LANDSCAPE 329 16.1 INTRODUCTION 329 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023–JUNE 2026 329 16.3 REVENUE ANALYSIS 331 16.4 MARKET SHARE ANALYSIS, 2025 332 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 334 16.5.1 STARS 335 16.5.2 EMERGING LEADERS 335 16.5.3 PERVASIVE PLAYERS 335 16.5.4 PARTICIPANTS 335 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 337 16.5.5.1 Company footprint 337 16.5.5.2 Region footprint 338 16.5.5.3 Product footprint 339 16.5.5.4 Application footprint 340 16.5.5.5 Species footprint 341 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 342 16.6.1 PROGRESSIVE COMPANIES 342 16.6.2 RESPONSIVE COMPANIES 342 16.6.3 DYNAMIC COMPANIES 342 16.6.4 STARTING BLOCKS 342 16.6.5 COMPETITIVE BENCHMARKING 344 16.6.5.1 Detailed list of key startups/SMEs 344 16.6.5.2 Competitive benchmarking of key startups/SMEs 345 16.7 COMPANY VALUATION AND FINANCIAL METRICS 346 16.7.1 COMPANY VALUATION 346 16.7.2 FINANCIAL METRICS 346 16.8 BRAND COMPARISON 347 16.9 COMPETITIVE SCENARIO 348 16.9.1 PRODUCT LAUNCHES 348 16.9.2 DEALS 349 16.9.3 EXPANSIONS 350 17 COMPANY PROFILES 351 17.1 KEY PLAYERS 351 17.1.1 THERMO FISHER SCIENTIFIC INC. 351 17.1.1.1 Business overview 351 17.1.1.2 Products offered 352 17.1.1.3 Recent developments 355 17.1.1.3.1 Product launches 355 17.1.1.3.2 Deals 355 17.1.1.4 MnM view 356 17.1.1.4.1 Key strengths 356 17.1.1.4.2 Strategic choices 356 17.1.1.4.3 Weaknesses and competitive threats 356 17.1.2 MERCK KGAA 357 17.1.2.1 Business overview 357 17.1.2.2 Products offered 359 17.1.2.3 Recent developments 363 17.1.2.3.1 Deals 363 17.1.2.3.2 Expansions 363 17.1.2.4 MnM view 363 17.1.2.4.1 Key strengths 363 17.1.2.4.2 Strategic choices 364 17.1.2.4.3 Weaknesses and competitive threats 364 17.1.3 BIO-TECHNE 365 17.1.3.1 Business overview 365 17.1.3.2 Products offered 366 17.1.3.3 Recent developments 370 17.1.3.3.1 Product launches 370 17.1.3.3.2 Deals 371 17.1.3.4 MnM view 371 17.1.3.4.1 Key strengths 371 17.1.3.4.2 Strategic choices 371 17.1.3.4.3 Weaknesses and competitive threats 371 17.1.4 DANAHER CORPORATION 372 17.1.4.1 Business overview 372 17.1.4.2 Products offered 373 17.1.4.3 Recent developments 377 17.1.4.3.1 Product launches 377 17.1.4.3.2 Deals 377 17.1.4.4 MnM view 378 17.1.4.4.1 Key strengths 378 17.1.4.4.2 Strategic choices 378 17.1.4.4.3 Weaknesses and competitive threats 378 17.1.5 REVVITY 379 17.1.5.1 Business overview 379 17.1.5.2 Products offered 380 17.1.5.3 Recent developments 385 17.1.5.3.1 Expansions 385 17.1.5.4 MnM view 385 17.1.5.4.1 Key strengths 385 17.1.5.4.2 Strategic choices 385 17.1.5.4.3 Weaknesses and competitive threats 385 17.1.6 BIO-RAD LABORATORIES, INC. 386 17.1.6.1 Business overview 386 17.1.6.2 Products offered 387 17.1.6.3 Recent developments 390 17.1.6.3.1 Product launches 390 17.1.7 BPS BIOSCIENCE, INC. 391 17.1.7.1 Business overview 391 17.1.7.2 Products offered 391 17.1.8 SARTORIUS AG 395 17.1.8.1 Business overview 395 17.1.8.2 Products offered 396 17.1.9 SINO BIOLOGICAL, INC. 400 17.1.9.1 Business overview 400 17.1.9.2 Products offered 400 17.1.10 GENSCRIPT 405 17.1.10.1 Business overview 405 17.1.10.2 Products offered 406 17.1.11 PROTEINTECH GROUP, INC. 411 17.1.11.1 Business overview 411 17.1.11.2 Products offered 411 17.1.11.3 Recent developments 413 17.1.11.3.1 Deals 413 17.1.12 MILTENYI BIOTEC 414 17.1.12.1 Business overview 414 17.1.12.2 Products offered 414 17.1.12.3 Recent developments 417 17.1.12.3.1 Product launches 417 17.1.13 ENZO BIOCHEM, INC. 418 17.1.13.1 Business overview 418 17.1.13.2 Products offered 418 17.1.13.3 Recent developments 421 17.1.13.3.1 Deals 421 17.1.14 ABNOVA CORPORATION 422 17.1.14.1 Business overview 422 17.1.14.2 Products offered 423 17.2 OTHER PLAYERS 427 17.2.1 STEMCELL TECHNOLOGIES 427 17.2.2 RAYBIOTECH, INC. 428 17.2.3 PROSPEC-TANY TECHNOGENE LTD. 429 17.2.4 PROTEOGENIX 430 17.2.5 AVIVA SYSTEMS BIOLOGY CORPORATION 432 17.2.6 ELABSCIENCE 433 17.2.7 QKINE LTD. 435 17.2.8 ABBEXA 436 17.2.9 BON OPUS BIOSCIENCES, LLC 437 17.2.10 NOVOPROTEIN SCIENTIFIC INC. 439 17.2.11 ORIGENE TECHNOLOGIES, INC. 440 18 RESEARCH METHODOLOGY 442 18.1 RESEARCH DATA 442 18.1.1 SECONDARY DATA 443 18.1.1.1 Key data from secondary sources 443 18.1.2 PRIMARY DATA 444 18.1.2.1 Key data from primary sources 444 18.1.2.2 Key primary participants 444 18.1.2.3 Breakdown of primary interviews 445 18.1.2.4 Key industry insights 446 18.2 MARKET SIZE ESTIMATION 446 18.2.1 GLOBAL RUO RECOMBINANT PROTEIN MARKET ESTIMATION, 2025 447 18.2.2 SEGMENTAL MARKET SIZE ESTIMATION 449 18.3 MARKET GROWTH RATE PROJECTIONS 451 18.4 DATA TRIANGULATION 452 18.5 FACTOR ANALYSIS 453 18.6 RESEARCH ASSUMPTIONS 453 18.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 454 19 APPENDIX 456 19.1 DISCUSSION GUIDE 456 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 460 19.3 CUSTOMIZATION OPTIONS 462 19.4 RELATED REPORTS 462 19.5 AUTHOR DETAILS 463

圖表清單 List of Tables & Figures

TABLE 1 RUO RECOMBINANT PROTEIN MARKET: INCLUSIONS AND EXCLUSIONS 39 TABLE 2 RUO RECOMBINANT PROTEIN MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 52 TABLE 3 KEY PIPELINE PRODUCTS IN STEM CELL THERAPY (AS OF 2025) 54 TABLE 4 RUO RECOMBINANT PROTEIN MARKET: PORTER’S FIVE FORCES 62 TABLE 5 RUO RECOMBINANT PROTEIN MARKET: ROLE OF PLAYERS IN ECOSYSTEM 69 TABLE 6 AVERAGE SELLING PRICE TREND OF RESEARCH-USE RECOMBINANT PROTEINS, BY KEY PLAYER, 2023–2025 (USD) 71 TABLE 7 AVERAGE SELLING PRICE TREND OF RUO RECOMBINANT PROTEINS, BY REGION, 2023–2025 (USD) 72 TABLE 8 IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 74 TABLE 9 EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 75 TABLE 10 RUO RECOMBINANT PROTEIN MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–JUNE 2027 76 TABLE 11 RECIPROCAL TARIFF RATES ADJUSTED BY US 80 TABLE 12 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 82 TABLE 13 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025 90 TABLE 14 LIST OF KEY PATENTS IN RUO RECOMBINANT PROTEIN MARKET, 2023–2025 92 TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN RUO RECOMBINANT PROTEIN MARKET 95 TABLE 16 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED RECOMBINANT PROTEIN SOLUTIONS IN RUO RECOMBINANT PROTEIN MARKET 97 TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99 TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99 TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101 TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 110 TABLE 22 KEY BUYING CRITERIA, BY END USER 111 TABLE 23 RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 115 TABLE 24 RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY REGION, 2024–2031 (USD MILLION) 116 TABLE 25 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 26 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 27 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 28 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 29 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 30 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 31 RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 32 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 33 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 34 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 35 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 36 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 37 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 38 RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 39 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 40 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 41 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 42 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 43 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 44 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 45 RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 46 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 47 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 48 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 49 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 50 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 51 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 52 RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 53 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 54 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 55 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 56 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 57 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 58 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 59 RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 60 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 61 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 62 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 63 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 64 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 65 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 66 RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 67 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 68 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 69 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 70 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 71 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 72 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 73 RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 141 TABLE 74 RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 75 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 76 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 77 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 78 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 79 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 80 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 81 RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 82 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 83 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 84 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 85 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 86 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 87 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 88 RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 150 TABLE 89 HUMAN RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 90 NORTH AMERICA: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 91 EUROPE: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 92 ASIA PACIFIC: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 93 LATIN AMERICA: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 94 MIDDLE EAST: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 95 GCC COUNTRIES: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 96 MOUSE RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 154 TABLE 97 NORTH AMERICA: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 98 EUROPE: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 99 ASIA PACIFIC: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 100 LATIN AMERICA: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 101 MIDDLE EAST: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 157 TABLE 102 GCC COUNTRIES: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 103 RAT RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 104 NORTH AMERICA: RAT RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 105 EUROPE: RAT RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 106 ASIA PACIFIC: RAT RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 107 LATIN AMERICA: RAT RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 108 MIDDLE EAST: RAT RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 160 TABLE 109 GCC COUNTRIES: RAT RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 110 NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 161 TABLE 111 NORTH AMERICA: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 112 EUROPE: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 113 ASIA PACIFIC: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 114 LATIN AMERICA: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 115 MIDDLE EAST: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 116 GCC COUNTRIES: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 117 RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES, BY REGION, 2024–2031 (USD MILLION) 165 TABLE 118 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 119 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 120 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 121 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 122 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 123 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 124 RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 169 TABLE 125 RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY REGION, 2024–2031 (USD MILLION) 170 TABLE 126 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 127 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 128 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 129 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 130 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY REGION, 2024–2031 (USD MILLION) 172 TABLE 131 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 132 RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 133 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 134 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 135 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 136 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 137 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS, BY REGION, 2024–2031 (USD MILLION) 176 TABLE 138 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 139 RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS, BY REGION, 2024–2031 (USD MILLION) 177 TABLE 140 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 141 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 142 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 143 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 144 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS, BY REGION, 2024–2031 (USD MILLION) 179 TABLE 145 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 146 RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY REGION, 2024–2031 (USD MILLION) 180 TABLE 147 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 148 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 149 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 150 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 151 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY REGION, 2024–2031 (USD MILLION) 183 TABLE 152 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 153 RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY REGION, 2024–2031 (USD MILLION) 184 TABLE 154 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 155 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 156 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 157 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 158 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY REGION, 2024–2031 (USD MILLION) 186 TABLE 159 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 160 RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 188 TABLE 161 RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY REGION, 2024–2031 (USD MILLION) 189 TABLE 162 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 163 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 164 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 165 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 166 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY REGION, 2024–2031 (USD MILLION) 191 TABLE 167 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 168 RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION) 192 TABLE 169 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 170 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 171 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 172 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 173 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION) 195 TABLE 174 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 175 RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY REGION, 2024–2031 (USD MILLION) 196 TABLE 176 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 177 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 178 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 179 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 180 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY REGION, 2024–2031 (USD MILLION) 198 TABLE 181 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 182 RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY REGION, 2024–2031 (USD MILLION) 199 TABLE 183 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 184 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 185 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 186 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 187 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY REGION, 2024–2031 (USD MILLION) 202 TABLE 188 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 189 RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY REGION, 2024–2031 (USD MILLION) 203 TABLE 190 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 191 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 192 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 193 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 194 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY REGION, 2024–2031 (USD MILLION) 205 TABLE 195 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 196 RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 206 TABLE 197 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 198 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 199 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 200 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 201 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 209 TABLE 202 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 203 RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 211 TABLE 204 RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 212 TABLE 205 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 206 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 207 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 208 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 209 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 215 TABLE 210 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 215 TABLE 211 RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 216 TABLE 212 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 213 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 214 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 215 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 216 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 218 TABLE 217 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 218 RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 219 TABLE 219 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 220 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 221 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 222 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 223 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 222 TABLE 224 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 225 RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 223 TABLE 226 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 227 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 228 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 229 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 230 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 225 TABLE 231 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 232 RUO RECOMBINANT PROTEIN MARKET, BY REGION, 2024–2031 (USD MILLION) 227 TABLE 233 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 229 TABLE 234 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 229 TABLE 235 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 230 TABLE 236 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 230 TABLE 237 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 231 TABLE 238 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 231 TABLE 239 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 232 TABLE 240 US: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 233 TABLE 241 US: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 233 TABLE 242 US: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 234 TABLE 243 US: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 234 TABLE 244 US: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 235 TABLE 245 US: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 235 TABLE 246 CANADA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 236 TABLE 247 CANADA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 237 TABLE 248 CANADA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 237 TABLE 249 CANADA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 238 TABLE 250 CANADA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 238 TABLE 251 CANADA: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 239 TABLE 252 EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 240 TABLE 253 EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 240 TABLE 254 EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 241 TABLE 255 EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 241 TABLE 256 EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 242 TABLE 257 EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 242 TABLE 258 EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 243 TABLE 259 GERMANY: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 244 TABLE 260 GERMANY: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 244 TABLE 261 GERMANY: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 245 TABLE 262 GERMANY: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 245 TABLE 263 GERMANY: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246 TABLE 264 GERMANY: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 265 UK: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 247 TABLE 266 UK: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 248 TABLE 267 UK: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 248 TABLE 268 UK: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 249 TABLE 269 UK: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 249 TABLE 270 UK: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 250 TABLE 271 FRANCE: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 251 TABLE 272 FRANCE: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 251 TABLE 273 FRANCE: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 252 TABLE 274 FRANCE: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 252 TABLE 275 FRANCE: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 253 TABLE 276 FRANCE: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 253 TABLE 277 ITALY: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 254 TABLE 278 ITALY: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 255 TABLE 279 ITALY: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 255 TABLE 280 ITALY: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 256 TABLE 281 ITALY: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 256 TABLE 282 ITALY: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 257 TABLE 283 SPAIN: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 258 TABLE 284 SPAIN: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 258 TABLE 285 SPAIN: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 259 TABLE 286 SPAIN: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 259 TABLE 287 SPAIN: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 260 TABLE 288 SPAIN: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 260 TABLE 289 REST OF EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 261 TABLE 290 REST OF EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 262 TABLE 291 REST OF EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 262 TABLE 292 REST OF EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 263 TABLE 293 REST OF EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263 TABLE 294 REST OF EUROPE: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 264 TABLE 295 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 296 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 266 TABLE 297 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 266 TABLE 298 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 267 TABLE 299 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 267 TABLE 300 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 268 TABLE 301 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 268 TABLE 302 CHINA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 269 TABLE 303 CHINA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 270 TABLE 304 CHINA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 270 TABLE 305 CHINA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 271 TABLE 306 CHINA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 271 TABLE 307 CHINA: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 272 TABLE 308 JAPAN: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 273 TABLE 309 JAPAN: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 273 TABLE 310 JAPAN: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 274 TABLE 311 JAPAN: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 274 TABLE 312 JAPAN: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 275 TABLE 313 JAPAN: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 275 TABLE 314 INDIA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 276 TABLE 315 INDIA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 277 TABLE 316 INDIA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 277 TABLE 317 INDIA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 278 TABLE 318 INDIA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 278 TABLE 319 INDIA: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 279 TABLE 320 AUSTRALIA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 280 TABLE 321 AUSTRALIA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 280 TABLE 322 AUSTRALIA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 281 TABLE 323 AUSTRALIA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 281 TABLE 324 AUSTRALIA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 282 TABLE 325 AUSTRALIA: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 282 TABLE 326 SOUTH KOREA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 283 TABLE 327 SOUTH KOREA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 284 TABLE 328 SOUTH KOREA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 284 TABLE 329 SOUTH KOREA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 285 TABLE 330 SOUTH KOREA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 285 TABLE 331 SOUTH KOREA: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 286 TABLE 332 REST OF ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 287 TABLE 333 REST OF ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 287 TABLE 334 REST OF ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 288 TABLE 335 REST OF ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 288 TABLE 336 REST OF ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 289 TABLE 337 REST OF ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 289 TABLE 338 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 290 TABLE 339 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 291 TABLE 340 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 291 TABLE 341 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 292 TABLE 342 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 292 TABLE 343 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 293 TABLE 344 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 293 TABLE 345 BRAZIL: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 294 TABLE 346 BRAZIL: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 295 TABLE 347 BRAZIL: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 295 TABLE 348 BRAZIL: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 296 TABLE 349 BRAZIL: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 296 TABLE 350 BRAZIL: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 297 TABLE 351 MEXICO: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 298 TABLE 352 MEXICO: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 298 TABLE 353 MEXICO: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 299 TABLE 354 MEXICO: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 299 TABLE 355 MEXICO: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 300 TABLE 356 MEXICO: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 300 TABLE 357 REST OF LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 301 TABLE 358 REST OF LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 302 TABLE 359 REST OF LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 302 TABLE 360 REST OF LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 303 TABLE 361 REST OF LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 303 TABLE 362 REST OF LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 304 TABLE 363 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 304 TABLE 364 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 305 TABLE 365 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 305 TABLE 366 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 306 TABLE 367 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 306 TABLE 368 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 307 TABLE 369 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 307 TABLE 370 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 308 TABLE 371 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 308 TABLE 372 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 309 TABLE 373 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 309 TABLE 374 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 310 TABLE 375 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 310 TABLE 376 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 311 TABLE 377 SAUDI ARABIA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 312 TABLE 378 SAUDI ARABIA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 312 TABLE 379 SAUDI ARABIA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 313 TABLE 380 SAUDI ARABIA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 313 TABLE 381 SAUDI ARABIA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 314 TABLE 382 SAUDI ARABIA: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 314 TABLE 383 UAE: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 315 TABLE 384 UAE: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 316 TABLE 385 UAE: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 316 TABLE 386 UAE: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 317 TABLE 387 UAE: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 317 TABLE 388 UAE: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 318 TABLE 389 REST OF GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 319 TABLE 390 REST OF GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 319 TABLE 391 REST OF GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 320 TABLE 392 REST OF GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 320 TABLE 393 REST OF GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 321 TABLE 394 REST OF GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 321 TABLE 395 REST OF MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 322 TABLE 396 REST OF MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 323 TABLE 397 REST OF MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 323 TABLE 398 REST OF MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 324 TABLE 399 REST OF MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 324 TABLE 400 REST OF MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 325 TABLE 401 AFRICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 326 TABLE 402 AFRICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 326 TABLE 403 AFRICA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 327 TABLE 404 AFRICA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL, 2024–2031 (USD MILLION) 327 TABLE 405 AFRICA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 328 TABLE 406 AFRICA: RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 328 TABLE 407 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN RUO RECOMBINANT PROTEIN MARKET, JANUARY 2023–JUNE 2026 329 TABLE 408 RUO RECOMBINANT PROTEIN MARKET: DEGREE OF COMPETITION 333 TABLE 409 RUO RECOMBINANT PROTEIN MARKET: REGION FOOTPRINT 338 TABLE 410 RUO RECOMBINANT PROTEIN MARKET: PRODUCT FOOTPRINT 339 TABLE 411 RUO RECOMBINANT PROTEIN MARKET: APPLICATION FOOTPRINT 340 TABLE 412 RUO RECOMBINANT PROTEIN MARKET: SPECIES FOOTPRINT 341 TABLE 413 RUO RECOMBINANT PROTEIN MARKET: DETAILED LIST OF KEY STARTUPS/SMES 344 TABLE 414 RUO RECOMBINANT PROTEIN MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 345 TABLE 415 RUO RECOMBINANT PROTEIN MARKET: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 348 TABLE 416 RUO RECOMBINANT PROTEIN MARKET: DEALS, JANUARY 2023–JUNE 2026 349 TABLE 417 RUO RECOMBINANT PROTEIN MARKET: EXPANSIONS, JANUARY 2023–JUNE 2026 350 TABLE 418 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 351 TABLE 419 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 352 TABLE 420 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 355 TABLE 421 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–JUNE 2026 355 TABLE 422 MERCK KGAA: COMPANY OVERVIEW 357 TABLE 423 MERCK KGAA: PRODUCTS OFFERED 359 TABLE 424 MERCK KGAA: DEALS, JANUARY 2023–JUNE 2026 363 TABLE 425 MERCK KGAA: EXPANSIONS, JANUARY 2023–JUNE 2026 363 TABLE 426 BIO-TECHNE: COMPANY OVERVIEW 365 TABLE 427 BIO-TECHNE: PRODUCTS OFFERED 366 TABLE 428 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 370 TABLE 429 BIO-TECHNE: DEALS, JANUARY 2023–JUNE 2026 371 TABLE 430 DANAHER CORPORATION: COMPANY OVERVIEW 372 TABLE 431 DANAHER CORPORATION: PRODUCTS OFFERED 373 TABLE 432 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 377 TABLE 433 DANAHER CORPORATION: DEALS, JANUARY 2023–JUNE 2026 377 TABLE 434 REVVITY: COMPANY OVERVIEW 379 TABLE 435 REVVITY: PRODUCTS OFFERED 380 TABLE 436 REVVITY: EXPANSIONS, JANUARY 2023–JUNE 2026 385 TABLE 437 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 386 TABLE 438 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 387 TABLE 439 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 390 TABLE 440 BPS BIOSCIENCE, INC.: COMPANY OVERVIEW 391 TABLE 441 BPS BIOSCIENCE, INC.: PRODUCTS OFFERED 391 TABLE 442 SARTORIUS AG: COMPANY OVERVIEW 395 TABLE 443 SARTORIUS AG: PRODUCTS OFFERED 396 TABLE 444 SINO BIOLOGICAL, INC.: COMPANY OVERVIEW 400 TABLE 445 SINO BIOLOGICAL, INC.: PRODUCTS OFFERED 400 TABLE 446 GENSCRIPT: COMPANY OVERVIEW 405 TABLE 447 GENSCRIPT: PRODUCTS OFFERED 406 TABLE 448 PROTEINTECH GROUP, INC.: COMPANY OVERVIEW 411 TABLE 449 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED 411 TABLE 450 PROTEINTECH GROUP, INC.: DEALS, JANUARY 2023–JUNE 2026 413 TABLE 451 MILTENYI BIOTEC: COMPANY OVERVIEW 414 TABLE 452 MILTENYI BIOTEC: PRODUCTS OFFERED 414 TABLE 453 MILTENYI BIOTEC: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 417 TABLE 454 ENZO BIOCHEM, INC.: COMPANY OVERVIEW 418 TABLE 455 ENZO BIOCHEM, INC.: PRODUCTS OFFERED 418 TABLE 456 ENZO BIOCHEM, INC.: DEALS, JANUARY 2023–JUNE 2026 421 TABLE 457 ABNOVA CORPORATION: COMPANY OVERVIEW 422 TABLE 458 ABNOVA CORPORATION: PRODUCTS OFFERED 423 TABLE 459 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW 427 TABLE 460 RAYBIOTECH, INC.: COMPANY OVERVIEW 428 TABLE 461 PROSPEC-TANY TECHNOGENE LTD.: COMPANY OVERVIEW 429 TABLE 462 PROTEOGENIX: COMPANY OVERVIEW 430 TABLE 463 AVIVA SYSTEMS BIOLOGY CORPORATION: COMPANY OVERVIEW 432 TABLE 464 ELABSCIENCE: COMPANY OVERVIEW 433 TABLE 465 QKINE LTD.: COMPANY OVERVIEW 435 TABLE 466 ABBEXA: COMPANY OVERVIEW 436 TABLE 467 BON OPUS BIOSCIENCES, LLC: COMPANY OVERVIEW 437 TABLE 468 NOVOPROTEIN SCIENTIFIC INC.: COMPANY OVERVIEW 439 TABLE 469 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW 440 TABLE 470 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 453 TABLE 471 RISK ASSESSMENT 455 FIGURE 1 RUO RECOMBINANT PROTEIN MARKET SEGMENTATION AND REGIONS CONSIDERED 38 FIGURE 2 RUO RECOMBINANT PROTEIN MARKET: YEARS CONSIDERED 39 FIGURE 3 MARKET SCENARIO 42 FIGURE 4 GLOBAL RUO RECOMBINANT PROTEIN MARKET, 2024–2031 42 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN RUO RECOMBINANT PROTEIN MARKET, 2023–2026 43 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF RUO RECOMBINANT PROTEIN MARKET 44 FIGURE 7 HIGH-GROWTH SEGMENTS IN RUO RECOMBINANT PROTEIN MARKET, 2026–2031 45 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN RUO RECOMBINANT PROTEIN MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 46 FIGURE 9 RISING ADOPTION OF CELL-BASED THERAPIES AND REGENERATIVE MEDICINE TO DRIVE MARKET GROWTH 47 FIGURE 10 LYOPHILIZED RECOMBINANT PROTEINS ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 48 FIGURE 11 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET TILL 2031 49 FIGURE 12 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 50 FIGURE 13 RUO RECOMBINANT PROTEIN MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52 FIGURE 14 RUO RECOMBINANT PROTEIN MARKET: PORTER’S FIVE FORCES ANALYSIS 63 FIGURE 15 RUO RECOMBINANT PROTEIN MARKET: VALUE CHAIN ANALYSIS 67 FIGURE 16 RUO RECOMBINANT PROTEIN MARKET: ECOSYSTEM ANALYSIS 69 FIGURE 17 AVERAGE SELLING PRICE OF RESEARCH-USE RECOMBINANT PROTEINS, BY KEY PLAYER, 2025 (USD) 72 FIGURE 18 AVERAGE SELLING PRICE OF RESEARCH-USE RECOMBINANT PROTEINS, BY REGION, 2025 (USD) 73 FIGURE 19 RUO RECOMBINANT PROTEIN MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77 FIGURE 20 INVESTMENT AND FUNDING SCENARIO, 2023–2025 (USD MILLION) 78 FIGURE 21 PATENT APPLICATIONS IN RUO RECOMBINANT PROTEIN MARKET, JANUARY 2015–DECEMBER 2025 91 FIGURE 22 IMPACT OF AI/GEN AI ON RUO RECOMBINANT PROTEIN MARKET 94 FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 109 FIGURE 24 KEY BUYING CRITERIA, BY END USER 110 FIGURE 25 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET SNAPSHOT 228 FIGURE 26 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET SNAPSHOT 265 FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN RUO RECOMBINANT PROTEIN MARKET, 2021–2025 332 FIGURE 28 RUO RECOMBINANT PROTEIN MARKET SHARE ANALYSIS, 2025 333 FIGURE 29 RUO RECOMBINANT PROTEIN MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 336 FIGURE 30 RUO RECOMBINANT PROTEIN MARKET: COMPANY FOOTPRINT 337 FIGURE 31 RUO RECOMBINANT PROTEIN MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 343 FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 346 FIGURE 33 EV/EBITDA OF KEY VENDORS 346 FIGURE 34 RUO RECOMBINANT PROTEIN MARKET: BRAND COMPARATIVE ANALYSIS 347 FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 352 FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT (2025) 358 FIGURE 37 BIO-TECHNE: COMPANY SNAPSHOT (2025) 366 FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 373 FIGURE 39 REVVITY: COMPANY SNAPSHOT (2025) 380 FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 387 FIGURE 41 SARTORIUS AG: COMPANY SNAPSHOT (2025) 396 FIGURE 42 GENSCRIPT: COMPANY SNAPSHOT (2025) 406 FIGURE 43 ABNOVA CORPORATION: COMPANY SNAPSHOT (2024) 423 FIGURE 44 RUO RECOMBINANT PROTEIN MARKET: RESEARCH DESIGN 442 FIGURE 45 RUO RECOMBINANT PROTEIN MARKET: BREAKDOWN OF PRIMARIES 445 FIGURE 46 RUO RECOMBINANT PROTEIN MARKET: INSIGHTS FROM PRIMARIES 446 FIGURE 47 GLOBAL RUO RECOMBINANT PROTEIN MARKET ESTIMATION, 2025 447 FIGURE 48 RUO RECOMBINANT PROTEIN MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 448 FIGURE 49 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2025) 448 FIGURE 50 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 449 FIGURE 51 RUO RECOMBINANT PROTEIN MARKET: CAGR PROJECTIONS 451 FIGURE 52 RUO RECOMBINANT PROTEIN MARKET: DATA TRIANGULATION 452

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們